Skip to main content
Journal cover image

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.

Publication ,  Journal Article
Smith, MA; Gorlick, R; Kolb, EA; Lock, R; Carol, H; Maris, JM; Keir, ST; Morton, CL; Reynolds, CP; Kang, MH; Arts, J; Bashir, T; Janicot, M ...
Published in: Pediatr Blood Cancer
August 2012

JNJ-26854165 was originally developed as an activator of p53 capable of inducing apoptosis in cancer cell lines. In vitro, JNJ-26854165 demonstrated cytotoxic activity. The ALL cell line panel had a significantly lower median IC(50) (0.85 µM) than the remaining cell lines. In vivo JNJ-26854165 induced significant differences in EFS distribution compared to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable ALL xenografts. Objective responses were observed in 4 of 37 solid tumor xenografts, and 2 of 7 ALL xenografts achieved PR or CR. Responses were noted in xenografts with both mutant and wild-type p53.

Duke Scholars

Published In

Pediatr Blood Cancer

DOI

EISSN

1545-5017

Publication Date

August 2012

Volume

59

Issue

2

Start / End Page

329 / 332

Location

United States

Related Subject Headings

  • Xenograft Model Antitumor Assays
  • Tumor Suppressor Protein p53
  • Tumor Cells, Cultured
  • Tryptamines
  • Sarcoma
  • Radiation-Sensitizing Agents
  • Proto-Oncogene Proteins c-mdm2
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Oncology & Carcinogenesis
  • Neuroblastoma
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Smith, M. A., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., Maris, J. M., … Houghton, P. J. (2012). Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer, 59(2), 329–332. https://doi.org/10.1002/pbc.23319
Smith, Malcolm A., Richard Gorlick, E Anders Kolb, Richard Lock, Hernan Carol, John M. Maris, Stephen T. Keir, et al. “Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.Pediatr Blood Cancer 59, no. 2 (August 2012): 329–32. https://doi.org/10.1002/pbc.23319.
Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, et al. Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 Aug;59(2):329–32.
Smith, Malcolm A., et al. “Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.Pediatr Blood Cancer, vol. 59, no. 2, Aug. 2012, pp. 329–32. Pubmed, doi:10.1002/pbc.23319.
Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT, Houghton PJ. Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 Aug;59(2):329–332.
Journal cover image

Published In

Pediatr Blood Cancer

DOI

EISSN

1545-5017

Publication Date

August 2012

Volume

59

Issue

2

Start / End Page

329 / 332

Location

United States

Related Subject Headings

  • Xenograft Model Antitumor Assays
  • Tumor Suppressor Protein p53
  • Tumor Cells, Cultured
  • Tryptamines
  • Sarcoma
  • Radiation-Sensitizing Agents
  • Proto-Oncogene Proteins c-mdm2
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Oncology & Carcinogenesis
  • Neuroblastoma